Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
BriaCell Therapeutics ( (TSE:BCT) ) has issued an announcement.
BriaCell Therapeutics announced positive results from its Phase 2 Bria-IMT™ study, demonstrating survival and clinical benefits that meet or exceed those of existing FDA-approved therapies for metastatic breast cancer. The promising data, presented at the 2025 ASCO Annual Meeting, suggest that Bria-IMT™ could become a less toxic therapeutic option for heavily pre-treated patients, potentially supporting future Biologics License Application and commercialization efforts.
The most recent analyst rating on (TSE:BCT) stock is a Buy with a C$15.00 price target. To see the full list of analyst forecasts on BriaCell Therapeutics stock, see the TSE:BCT Stock Forecast page.
Spark’s Take on TSE:BCT Stock
According to Spark, TipRanks’ AI Analyst, TSE:BCT is a Neutral.
BriaCell Therapeutics has a challenging financial position with no revenue and consistent losses, heavily impacting its stock score. Despite this, recent corporate developments in cancer treatment provide some potential upside. Technical indicators are mixed, and valuation concerns persist with a negative P/E ratio. The company’s reliance on external financing is a notable risk.
To see Spark’s full report on TSE:BCT stock, click here.
More about BriaCell Therapeutics
BriaCell Therapeutics Corp. is a clinical-stage biotechnology company focused on developing novel immunotherapies to transform cancer care. The company is primarily engaged in the development of treatments for metastatic breast cancer, aiming to address urgent, unmet medical needs in this area.
Average Trading Volume: 16,607
Technical Sentiment Signal: Strong Sell
Current Market Cap: C$26.98M
See more data about BCT stock on TipRanks’ Stock Analysis page.